Treatment for people suffering from Covid vaccine-related blood clots found
The researchers at the McMaster University recommend a combination of anti-clotting drugs and high doses of intravenous immunoglobulin to combat vaccine-induced immune thrombotic thrombocytopenia (VITT). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 1, 2021 Category: Pharmaceuticals Source Type: news

Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine
What is believed to be the first case of vaccine-induced thrombosis with thrombocytopenia after a messenger RNA COVID-19 vaccine has been reported.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 28, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Case reports thrombocytopenia with thrombosis following COVID-19 mRNA vaccine
(American College of Physicians) A single case reports thrombocytopenia with thrombosis syndrome (TTS) following the mRNA-1273 vaccine for COVID-19. Previously, it was hypothesized that adenoviral vector-based vaccines were the sole cause of TTS or vaccine-induced TTS (VITT). The case is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 28, 2021 Category: Infectious Diseases Source Type: news

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
FREDERICK, Md., June 16, 2021 -- (Healthcare Sales & Marketing Network) -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical... Biopharmaceuticals, Venture Capital Veralox Therapeutics, 12-lipoxygenase, heparin-induced thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Thrombocytopenia and COVID-19 Severity and Outcome Thrombocytopenia and COVID-19 Severity and Outcome
This systematic review shows that thrombocytopenia is common in COVID-19, and is associated with COVID-19 severity and outcome.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mini bone marrow model predicts response to blood disorder treatment
(eLife) A new miniature 3D model of human bone marrow has been described today in the open-access eLife journal. The model may help clinicians predict which patients will benefit from a new therapy for blood platelet disorders, such as Inherited Thrombocytopenias -- a group of familial disorders that inhibit the production of platelets. It could also enable further study of these disorders and give scientists a new tool to test experimental treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2021 Category: International Medicine & Public Health Source Type: news

Eltrombopag may be cost effective for thrombocytopenia and PGF post transplantation
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Single SubQ Shot Offers Fast, Potent Platelet Inhibition in STEMI Single SubQ Shot Offers Fast, Potent Platelet Inhibition in STEMI
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CHMP issues further advice on thrombosis and thrombocytopenia with Vaxzevria (AstraZeneca's COVID-19 vaccine), EMA
Healthcare professionals are advised that Vaxzevria must not be administered to patients with thrombosis with thrombocytopenia syndrome after receiving the vaccine and patients should be monitored for thrombosis and thrombocytopenia within 3 weeks of vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 25, 2021 Category: Consumer Health News Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Statins side effects: Unusual bleeding from various body parts could be thrombocytopenia
STATINS side effects: Like all medicines, statins can cause side effects. But most people tolerate them well and do not have any problems. However, some do not and with low blood platelet count being a common side effect from the drug another more serious condition may develop causing unusual bleeding from various body parts. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2021 Category: Consumer Health News Source Type: news

Management of vaccine-induced thrombosis and thrombocytopenia, RCS
There are increasing reports of a rare adverse event of thrombosis and thrombocytopenia following the first dose of the AstraZeneca COVID-19 vaccine, a syndrome labelled vaccine-induced thrombotic thrombocytopenia syndrome (VITT). The colleges and surgical specialty associations have produced guidance on the features and management of VITT, taking into account vascular, gastrointestinal and neurosurgical considerations. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 14, 2021 Category: Consumer Health News Source Type: news

Canada reports 28 cases of rare blood clots following AstraZeneca vaccinations
After distributing more than 2.3 million AstraZeneca vaccine doses nationwide, public health officials have so far identified 28 suspected cases of a rare but serious condition called vaccine-induced thrombotic thrombocytopenia (VITT). (Source: CBC | Health)
Source: CBC | Health - May 13, 2021 Category: Consumer Health News Tags: News/Politics Source Type: news

Coronavirus live news: jabs like Pfizer and Moderna appear able to ‘neutralise’ Indian variant, says EMA
European medicines watchdog says there is‘promising evidence’ the vaccines work against variant first encountered in IndiaCovid pandemic was preventable, says WHO-commissioned reportChina has used pandemic to boost global image, report saysUK prime minister announces independent inquiry into Covid handlingSpike in India variant poses threat to UK reopening, scientists sayAustralia: fresh outbreak blamed on hotel quarantine leak4.49pmBSTCovid-related deaths in theUS have fallen to an average of around 600 per day — the lowest level in 10 months — with the number of lives lost dropping to single digit...
Source: Guardian Unlimited Science - May 12, 2021 Category: Science Authors: Mattha Busby (now); Tobi Thomas, Martin Belam and Martin Farrer (earlier) Tags: Coronavirus India UK news US news Brazil Science Americas World news Source Type: news

Guidance Issued for Managing CVST After COVID - 19 Vaccination
CVST with thrombocytopenia reported after COVID - 19 vaccine with adenoviral vector; management similar to heparin - induced thrombocytopenia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 11, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Infections, Internal Medicine, Emergency Medicine, Neurology, Nursing, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Coronavirus vaccine - summary of Yellow Card reporting (up to 28 April), MHRA
The overall case incidence of thromboembolic events with concurrent thrombocytopenia reported in recipients of the Covid-19 Vaccine AstraZeneca was 10.5 per million doses. There is now some evidence the rate is higher in females, although this is not seen across all age groups. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 10, 2021 Category: Consumer Health News Source Type: news

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 6, 2021 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Vaccination COVID-19 Coronavirus Disease 2019 Source Type: news

12 Cases of CVST Reported for Ad26.COV2.S Vaccine in the U.S.
TUESDAY, May 4, 2021 -- Twelve cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia have been reported following use of the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson& Johnson), which uses a human adenoviral vector,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2021 Category: Pharmaceuticals Source Type: news

MHRA reports latest Yellow Card reporting data for coronavirus vaccines, MHRA
Based on analysis of data up to 21 April, the overall case incidence of major thromboembolic events with concurrent thrombocytopenia reported in recipients of the Covid-19 Vaccine AstraZeneca was 9.3 per million doses (209 cases, including 84 of cerebral venous sinus thrombosis). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news

Emergency physicians first to safely treat vaccine-induced blood clot with heparin alternative
(American College of Emergency Physicians) A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2021 Category: International Medicine & Public Health Source Type: news

EARLY RELEASE: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 30, 2021 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Vaccination COVID-19 Coronavirus Disease 2019 Source Type: news

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021
The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 29, 2021 Category: American Health Tags: Advisory Committee on Immunization Practices (ACIP) MMWR Morbidity & Mortality Weekly Report COVID-19 Coronavirus Disease 2019 Source Type: news

Primary Care Management of Suspected Thromboembolism with Thrombocytopenia after COVID-19 Vaccination, RCGP
Serious thromboembolic events with concurrent thrombocytopenia have occurred very rarely following vaccination with AstraZeneca (AZ) COVID-19 vaccine. This includes venous thrombosis, sometimes involving unusual sites such as cerebral venous sinus thrombosis (CVST), splanchnic vein thrombosis, or arterial thrombosis, combined with thrombocytopenia. It is currently estimated that the overall incidence of CVST following the AZ vaccine is around 4 per million first doses administered. Suspected cases have been reported in patients of all ages and genders and currently, no specific predisposing factors have been identified. ...
Source: Current Awareness Service for Health (CASH) - April 26, 2021 Category: Consumer Health News Source Type: news

Are There Developmental Changes in Platelet Function for Children?
Discussion While most people realize that each stage of a child’s life is different, there are some areas that people do not realize are different. For example, there are many laboratory values which are different based on the age because there are developmental changes. Within the hematopoietic system there are many developmental changes that are common such as hemoglobin and hematocrit. Others are less well known such as children have quantitatively less fibrinogen, but the activity is the same as adult fibrinogen. Platelets are an important part of both the primary and secondary hemostasis processes. They develop ...
Source: PediatricEducation.org - April 26, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
NEW BRUNSWICK, N.J., April 23, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combin...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Use of the J & J Vaccine for COVID-19 Can Resume, Says CDC Review Panel
In a 10 to 4 vote, a committee of the U.S. Centers for Disease Control (CDC) on April 23 decided to lift the temporary hold on using the COVID-19 vaccine made by Johnson & Johnson/Janssen. The U.S. Food and Drug Administration (FDA) and CDC had temporarily halted vaccination with the J&J shot on April 13 after six reports of unusual blood clots in the brain occurred among nearly 7 million people vaccinated with the shot in the U.S. The panel of 15 independent experts was under some pressure to make a decision about the safety of the vaccine, which is the only single-shot vaccine for COVID-19 currently authorized in...
Source: TIME: Health - April 23, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) ReviewEMA Confirms Overall Benefit-Risk Profile Remains Positive
NEW BRUNSWICK, N.J., April 20, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company’s COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company’s COVID-19 vaccine. As a resul...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Management of patients presenting to the Emergency Department/ Acute Medicine with symptoms: Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT), RCEM/RCP/SAM
Guidance document on how to deal with a patient presenting to ED or acute medicine with COVID-19 vaccine-induced thrombosis and thrombocytopenia (VITT). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 19, 2021 Category: Consumer Health News Source Type: news

Management of patients presenting to the Emergency Department/ Acute Medicine with symptoms, RCEM
The condition of concern is Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 16, 2021 Category: Consumer Health News Source Type: news

Guidance produced from the Expert Haematology Panel (EHP) focussed on Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT), British Society of Haematology
There are currently no robust data to inform management of this condition. In the absence of evidence, these are pragmatic guidelines based on experience of managing alternative similar conditions and the theoretical risks and benefits of interventions. As evidence emerges, recommendations are expected to change. Patient management should be individualised according to specific circumstances. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 16, 2021 Category: Consumer Health News Source Type: news

FDA and CDC Recommend Pausing COVID-19 Vaccination With J & J-Janssen Shot While They Investigate Blood Clot Risks
The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are recommending that vaccinations with the Johnson & Johnson/Janssen COVID-19 vaccine be temporarily halted while the agencies review reports of blood clots among vaccinated people. On April 13, the two government agencies issued a joint statement announcing a recommended pause as federal regulators review six cases of blood clots reported six to 13 days after the people received the single-dose vaccine. “Until that [review] process is complete, we are recommending a pause in the use of this vaccine out of an abundance of cautio...
Source: TIME: Health - April 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Rare Thrombosis, Thrombocytopenia Seen After AstraZeneca COVID-19 Vaccine
TUESDAY, April 13, 2021 -- While rare, thrombosis and thrombocytopenia can occur after the ChAdOx1 nCoV-19 adenoviral vector vaccine against COVID-19 (AstraZeneca), according to two reports published online April 9 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). (Source: World Pharma News)
Source: World Pharma News - April 13, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

How worried should we be about blood clots linked to AstraZeneca and J & J vaccines?
With both the AstraZeneca and Johnson& Johnson (J&J)vaccines, the reports involve extremely rare clotting, including a type of blood clot called cerebral venous sinus thrombosis (CVST), that were seen in combination with low levels of blood platelets, called thrombocytopenia. (Source: The Economic Times)
Source: The Economic Times - April 13, 2021 Category: Consumer Health News Source Type: news

Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot. In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news

Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19, Frontiers in immunology
Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8 th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-o...
Source: Current Awareness Service for Health (CASH) - April 9, 2021 Category: Consumer Health News Source Type: news

EMA Again Reassures on AstraZeneca COVID Vaccine EMA Again Reassures on AstraZeneca COVID Vaccine
But the agency says it cannot rule out a link between rare and serious cases of thrombosis with thrombocytopenia with the vaccine.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 7, 2021 Category: Neurology Tags: Infectious Diseases News Source Type: news

AstraZeneca COVID Vaccine: Clotting Disorder Mechanism Revealed? AstraZeneca COVID Vaccine: Clotting Disorder Mechanism Revealed?
More information has become available indicating that the vaccine may be linked to a condition that clinically resembles heparin-induced thrombocytopenia and seems to occur mainly in younger women.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 1, 2021 Category: Cardiology Tags: Public Health & Prevention News Source Type: news

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ( " NDA " ) submission to the U.S. Food and Drug Administration ( " FDA " ) seeking... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 31, 2021 Category: Drugs & Pharmacology Source Type: news

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Commercial Preparations Underway to Support Potential Approval and Launch of Pacritinib in the United States in 2021 SEATTLE, March 31, 2021 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has com... Biopharmaceuticals, FDA CTI BioPharma, pacritinib, myelofibrosis, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 31, 2021 Category: Pharmaceuticals Source Type: news

Why Countries Around the World Are Suspending Use of AstraZeneca ’s COVID-19 Vaccine
It’s the last thing public health officials want to see in the midst of a pandemic: more than two months after pharmaceutical giant AstraZeneca and Oxford University scientists released their COVID-19 vaccine, countries in Europe and elsewhere are pausing its use amid disconcerting reports that a small number of recipients have experienced blood clots, some of them fatal. The European Medicines Agency, which oversees drugs and vaccines in Europe, is expected to issue a guidance on March 18 about whether the side effects were related to the vaccine after reviewing the reports; in the meantime, it says the benefits of ...
Source: TIME: Health - March 16, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Covid-19 vaccine safe, based on scientific evidence, AstraZeneca reassures the world
It further said that, a review of available safety data of more than 17 million people vaccinated in the European Union (EU) and UK with its vaccine has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 15, 2021 Category: Pharmaceuticals Source Type: news

Perioperative Platelet Transfusions Perioperative Platelet Transfusions
Platelet transfusion is the primary therapy for patients with thrombocytopenia or platelet dysfunction who require surgery. Review guidance on when and which type to use in this paper.Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2021 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

mRNA vaccines for the Wuhan coronavirus caused blood disorder in at least 36 people
(Natural News) The messenger RNA (mRNA) vaccines developed to fight the Wuhan coronavirus may have caused at least 36 individuals to develop a rare blood disorder. Either Moderna’s mRNA-1273 jab or the Pfizer/BioNTech BNT162b2 vaccine may have caused thrombocytopenia – which affects blood clotting – in these individuals. Both vaccines had reported more than 90... (Source: NaturalNews.com)
Source: NaturalNews.com - February 11, 2021 Category: Consumer Health News Source Type: news

36 people developed rare blood disorder after covid vaccination
At least 36 people have developed a rare, life-threatening blood disorder, called thrombocytopenia, after receiving either of the two COVID-19 vaccines authorized in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - February 9, 2021 Category: Consumer Health News Source Type: news